Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
Date:11/18/2009

n a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
2. YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
3. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
4. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
5. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
6. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
7. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
8. OriGene Technologies Acquires Marligen Biosciences
9. Cytopia Merger with Toronto-based YM BioSciences Inc.
10. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
11. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation ... executive promotions as well as changes to Martine ... Executive Promotions United Therapeutics announced the ... and Co-Chief Executive Officer and David Zaccardelli , ... In connection with these promotions, Dr. Rothblatt,s title will ...
(Date:12/17/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, announced today its presentation at the ... San Francisco, CA. ... will present on Monday, January 12, 2015, at 9:00 ... webcast live and may be accessed from the "Webcasts ...
(Date:12/15/2014)... 2014 Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology,  today celebrated continued ... its exVive3D TM Human Liver Tissue.  The ... commercial release on November 18, has been recognized ... awards for innovation. Most recently, on ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Microscope Series Positioned at the Center of the Most Advanced ... ... Instruments, Inc., (http://www.nikoninstruments.com ) today announced the launch of its ... the,new Ti offers improved system speed, increased flexibility and efficient,multi-mode ...
... - Canadian Biotechnology Company demonstrates the technical feasibility of ... in safflower - ... TSX symbol: SBS, ... company developing a portfolio of therapeutic,proteins for metabolic and cardiovascular diseases, ...
... Nominated Actress Shares Her Personal Story and Tips for Better Blood ... ... of the more,than 20 million Americans living with diabetes, Emmy nominated actress ... diabetes care, to urge other Americans with diabetes to reach,better levels of ...
Cached Biology Technology:Nikon Unveils the Eclipse Ti Inverted Microscope Series at The Society for Neroscience Annual Meeting 2Nikon Unveils the Eclipse Ti Inverted Microscope Series at The Society for Neroscience Annual Meeting 3SemBioSys announces 2007 third quarter results 2SemBioSys announces 2007 third quarter results 3SemBioSys announces 2007 third quarter results 4SemBioSys announces 2007 third quarter results 5SemBioSys announces 2007 third quarter results 6SemBioSys announces 2007 third quarter results 7SemBioSys announces 2007 third quarter results 8SemBioSys announces 2007 third quarter results 9SemBioSys announces 2007 third quarter results 10SemBioSys announces 2007 third quarter results 11SemBioSys announces 2007 third quarter results 12Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 2Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 3Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes 4
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Not knowing which way is up can have deadly ... spatial disorientation, is responsible for up to 10 percent ... 90 percent of these being fatal, according to the ... no spatial disorientation accidents in space, it is a ...
... feel the tell-tale tug of tiny concentrations of pathogens ... sterilizedor even heldas they are ephemeral and weightless. The ... a patented "optical tweezers" technique for detecting and measuring ... virus on a surface. NIST has issued a non-exclusive ...
... from satellites now allow scientists to monitor changes to water ... sheets and even under the ground. As the climate changes, ... predicting future impacts in different regions. Sea level rise ... it is much more difficult to model and predict than ...
Cached Biology News:Space researchers developing tool to help disoriented pilots 2Space researchers developing tool to help disoriented pilots 3Measuring water from space 2Measuring water from space 3
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
... Concentrated x 10 This pH 9.9 ... prior to immunohistochemical staining procedures. It is ... mounted on glass slides. For particular antigens, ... especially effective. It should be noted that ...
... SeMet White to off-white solid. ... ≥98% by HPLC. Soluble in H 2 ... prior to use. RTECS EK7713840, CAS 3211-76-5, ... 13, 8515.Jornot, L., and Junod, A.F. ...
Biology Products: